Using AD biomarker research results for clinical care: A survey of ADNI investigators

Neurology

Volumn 81, Issue 13, 2013, Pages 1114-1121

  Shulman, Melanie B ^a   Harkins, Kristin ^b   Green, Robert C ^c   Karlawish, Jason ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; TRACER; ANILINE DERIVATIVE; DIAGNOSTIC AGENT; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUORINE;

ALZHEIMER DISEASE; AMYLOID IMAGING RESULT; CEREBROSPINAL FLUID; COGNITION; DIAGNOSIS RELATED GROUP; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; HUMAN; INTERPERSONAL COMMUNICATION; INVESTIGATOR; MEDICAL RESEARCH; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NAMED GROUPS BY OCCUPATION; NEUROIMAGING; NEUROPSYCHOMETRY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONLINE SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOMETRY; RESEARCH ETHICS; REVIEW; STAFF; ARTICLE; ATTITUDE; BRAIN; EDUCATIONAL STATUS; FEMALE; HEALTH SURVEY; MALE; METABOLISM; PATHOLOGY; PERSONNEL; PSYCHOLOGICAL ASPECT; SCINTISCANNING; UNITED STATES;

ALZHEIMER DISEASE; ANILINE COMPOUNDS; ATTITUDE; BIOLOGICAL MARKERS; BRAIN; EDUCATIONAL STATUS; ETHYLENE GLYCOLS; FEMALE; FLUORINE RADIOISOTOPES; HEALTH SURVEYS; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; RESEARCH PERSONNEL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84887427371     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a55f4a     Document Type: Review

References (21)

1. Alzheimer's Disease Neuroimaging Initiative. Clinicaltrials. gov identifier: NCT00106899 [online]. Available at: http://clinicaltrials.gov/show/ NCT00106899. Accessed January 16, 2013.
2. Miller G. Alzheimer's biomarker initiative hits its stride. Science 2009;326:386-389.
3. Alzheimer's Disease Neuroimaging Initiative. ADNI protocol [online]. Available at: http://adni-info.org/PPSB/Pdfs/adni-protocol-03.02.2005-ss.pdf. Accessed January 16, 2013.
4. Fabsitz RR, McGuire A, Sharp RR, et al; National Heart, Lung, and Blood Institute Working Group. Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute Working Group. Circ Cardiovasc Genet 2010;3:574-580.
5. Bredenoord A, Kroes H, Cuppen E, Parker M, vanDelden JJ. Disclosure of individual genetic data to research participants: The debate reconsidered. Trends Genet 2011; 27:41-47.
6. Dressler LG. Disclosure of research results from cancer genomic studies: state of the science. Clin Cancer Res 2009;15:4270-4276.
7. U.S. Food and Drug Administration. FDA approves imaging drug Amyvid [online]. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm299678.htm. Accessed April 10, 2012.
8. Dillman D. Mail and Internet Surveys: The Tailored Design Method. New York: John Wiley; 2000.
9. Karlawish J. Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 2011; 77:1487-1493.
10. Reiman EM, Langbaum JBS, Fleisher AS, et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011;26(suppl 3):321-329.
11. Sperling R, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011;3:111-13.
12. Shalowitz DI, Miller FG. Communicating the results of clinical research to participants: Attitudes, practices, and future directions. PLoS Med 2008;5:e91.
13. Salmon D, Lineweaver T, Bondi M, Galasko D. Knowledge of APOE genotype affects subjective and objective memory performance in healthy older adults. Alzheimers Dement 2012;8(4 suppl 2):123-124. Abstract.
14. Wolf SM, Crock BN, Van Ness B, et al. Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet Med 2012;14:361-384.
15. Levesque E, Joly Y, Simard J. Return of research results: general principles and international perspectives. J Law Med Ethics 2011;39:583-592.
16. Shalowitz DI, Miller FG. Disclosing individual results of clinical research: implications of respect for participants. JAMA 2005;294:737-740. (Pubitemid 41159294)
17. Partridge AH, Wong JS, Knudsen K, et al. Offering participants results of a clinical trial: sharing results of a negative study. Lancet 2005;365:963-964. (Pubitemid 41071430)
18. Smith CO, Lipe HP, Bird TD. Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol 2004;61:875-880. (Pubitemid 38747326)
19. Christensen KD, Roberts JS, Shalowitz DI, et al. Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev 2011;20:522-529.
20. Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009;361:245-254.
21. Kellerman SE, Herold J. Physician response to surveys: A review of the literature. Am J Prev Med 2001;20:61-67. (Pubitemid 32013069)